You are here : Home > Clinical Research UMR9199 LDM

Clinical Research

Published on 2 February 2017

The research teams of MIRCen collaborate closely with the clinical imaging center of Frédéric Joliot Hospital, one of the departments of the Institute of Biomedical Imaging, and the departments of neurology and neurosurgery of Henri Mondor Hospital (Paris XI University). These collaborations are developing innovative treatments for neurodegenerative diseases in the framework of a translational approach.

Expertise and Equipment at Frédéric Joliot Hospital

par-20110307-061_img_medium.jpg 

PET, SPECT and MRI brain imaging platform:

 

cyclotron-shfj_img_medium.jpg 
Cyclotron at the SHFJ facility

 

  • A 15 MeV cyclotron for the production of positron emitters
  • Nonradioactive chemistry and radiochemistry laboratories for the preparation of radiopharmaceuticals in accordance with good manufacturing practice
  • Three positron emission tomographs, including a system with very high spatial resolution for brain imaging
  • A system for bimodal PET and TDM (tomodensitometry) imaging
  • Two gamma cameras for scintigraphy and single-photon emission computed tomography (SPECT)
  • A 1.5 T MRI system
  • A set of tools for advanced image processing, including pharmacokinetic modeling and multimodal image analysis

  • Four day-hospital rooms

At Henri Mondor Hospital :

hopital-henri-mondor-de-creteil_medium.jpg 

  • A neurology department with expertise in the domain of neurodegenerative diseases (Parkinson’s, Alzheimer’s, multiple sclerosis and national expert center for Huntington’s disease), with large cohorts of patients
  • Expertise in cognitive aspects of neurodegenerative diseases (including language, collaboration with the Ecole Normale Supérieure)
  • A neurosurgery department equipped for stereotactic surgery and specializing in biotherapy (gene transfer and cell therapy)
  • A clinical investigation center for biotherapy
  • An electrophysiology laboratory
  • Dedicated rooms and qualified staff, making it possible to carry out complete clinical trials in biosafety level 2 conditions (surgery and tests on patients)
  • Quantitative motor evaluation (video analysis of movement)
  • An MRI system

Principal Results

  • 20 years of experience with clinical brain imaging in patients with Parkinson’s and Huntington’s diseases (funding from the Ministry of Health and private foundations)
  • International expertise in the clinical transplantation of cells for Parkinson’s and Huntington’s diseases (Prof. Stéphane Palfi, Prof. Philippe Remy, Prof. Bachoud-Lévy)
  • First European clinical trial of gene therapy in vivo for Parkinson’s disease, funded by Oxford Biomedica Ltd. (Prof. Stéphane Palfi, Prof. Philippe Remy, Clinical Imaging Theme)
  • High-frequency cortical stimulation for the treatment of Parkinson’s disease and movement disorders (Prof. Stéphane Palfi, Prof. Philippe Remy, Clinical Imaging Theme)

  • Coordination of the national Huntington’s disease network (Prof. Bachoud-Lévy).